Antifungal drugs: New insights in research & development

The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology & therapeutics (Oxford) 2019-03, Vol.195, p.21-38
Hauptverfasser: Nicola, André Moraes, Albuquerque, Patrícia, Paes, Hugo Costa, Fernandes, Larissa, Costa, Fabricio F., Kioshima, Erika Seki, Abadio, Ana Karina Rodrigues, Bocca, Anamélia Lorenzetti, Felipe, Maria Sueli
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue
container_start_page 21
container_title Pharmacology & therapeutics (Oxford)
container_volume 195
creator Nicola, André Moraes
Albuquerque, Patrícia
Paes, Hugo Costa
Fernandes, Larissa
Costa, Fabricio F.
Kioshima, Erika Seki
Abadio, Ana Karina Rodrigues
Bocca, Anamélia Lorenzetti
Felipe, Maria Sueli
description The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.
doi_str_mv 10.1016/j.pharmthera.2018.10.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2138636087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016372581830192X</els_id><sourcerecordid>2138636087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</originalsourceid><addsrcrecordid>eNqFkEtPwzAMgCMEYmPwF1BPiEtLHm2TchsTL2mCC0jcoix11kx9kbRD_HsyjceRky37sy1_CEUEJwST_GqT9JVyzVCBUwnFRIRygrE4QFMieBEH5u0QTUNgMaeZmKAT7zcY4zTF9BhNGGYpp4ROkZi3gzVju1Z1VLpx7a-jJ_iIbOvtuhp8SCIHHpTTVXQRlbCFuusbaIdTdGRU7eHsO87Q693ty-IhXj7fPy7my1gzng4xZUUKOKMGlwXVaV5oohglucmMIJSH1GC64kSRrKQFKQk2kLHM5MAoT2HFZuhyv7d33fsIfpCN9RrqWrXQjV5SwkTOcix4QMUe1a7z3oGRvbONcp-SYLnzJjfyz5vcedt1grcwev59ZVw1UP4O_ogKwM0egPDr1oKTXltoNZTWgR5k2dn_r3wBvAuCBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138636087</pqid></control><display><type>article</type><title>Antifungal drugs: New insights in research &amp; development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</creator><creatorcontrib>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</creatorcontrib><description>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2018.10.008</identifier><identifier>PMID: 30347212</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Antibodies, Monoclonal - therapeutic use ; Antifungal Agents - therapeutic use ; Antifungal immunotherapy ; Biological Products - therapeutic use ; Drug Development ; Drug discovery and development ; Drug targets ; Essential genes ; Humans ; Immunotherapy ; Mycoses - therapy ; Rational drug design ; Systemic mycoses ; Vaccines - therapeutic use</subject><ispartof>Pharmacology &amp; therapeutics (Oxford), 2019-03, Vol.195, p.21-38</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</citedby><cites>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2018.10.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30347212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nicola, André Moraes</creatorcontrib><creatorcontrib>Albuquerque, Patrícia</creatorcontrib><creatorcontrib>Paes, Hugo Costa</creatorcontrib><creatorcontrib>Fernandes, Larissa</creatorcontrib><creatorcontrib>Costa, Fabricio F.</creatorcontrib><creatorcontrib>Kioshima, Erika Seki</creatorcontrib><creatorcontrib>Abadio, Ana Karina Rodrigues</creatorcontrib><creatorcontrib>Bocca, Anamélia Lorenzetti</creatorcontrib><creatorcontrib>Felipe, Maria Sueli</creatorcontrib><title>Antifungal drugs: New insights in research &amp; development</title><title>Pharmacology &amp; therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Antifungal immunotherapy</subject><subject>Biological Products - therapeutic use</subject><subject>Drug Development</subject><subject>Drug discovery and development</subject><subject>Drug targets</subject><subject>Essential genes</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Mycoses - therapy</subject><subject>Rational drug design</subject><subject>Systemic mycoses</subject><subject>Vaccines - therapeutic use</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtPwzAMgCMEYmPwF1BPiEtLHm2TchsTL2mCC0jcoix11kx9kbRD_HsyjceRky37sy1_CEUEJwST_GqT9JVyzVCBUwnFRIRygrE4QFMieBEH5u0QTUNgMaeZmKAT7zcY4zTF9BhNGGYpp4ROkZi3gzVju1Z1VLpx7a-jJ_iIbOvtuhp8SCIHHpTTVXQRlbCFuusbaIdTdGRU7eHsO87Q693ty-IhXj7fPy7my1gzng4xZUUKOKMGlwXVaV5oohglucmMIJSH1GC64kSRrKQFKQk2kLHM5MAoT2HFZuhyv7d33fsIfpCN9RrqWrXQjV5SwkTOcix4QMUe1a7z3oGRvbONcp-SYLnzJjfyz5vcedt1grcwev59ZVw1UP4O_ogKwM0egPDr1oKTXltoNZTWgR5k2dn_r3wBvAuCBQ</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Nicola, André Moraes</creator><creator>Albuquerque, Patrícia</creator><creator>Paes, Hugo Costa</creator><creator>Fernandes, Larissa</creator><creator>Costa, Fabricio F.</creator><creator>Kioshima, Erika Seki</creator><creator>Abadio, Ana Karina Rodrigues</creator><creator>Bocca, Anamélia Lorenzetti</creator><creator>Felipe, Maria Sueli</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Antifungal drugs: New insights in research &amp; development</title><author>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Antifungal immunotherapy</topic><topic>Biological Products - therapeutic use</topic><topic>Drug Development</topic><topic>Drug discovery and development</topic><topic>Drug targets</topic><topic>Essential genes</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Mycoses - therapy</topic><topic>Rational drug design</topic><topic>Systemic mycoses</topic><topic>Vaccines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nicola, André Moraes</creatorcontrib><creatorcontrib>Albuquerque, Patrícia</creatorcontrib><creatorcontrib>Paes, Hugo Costa</creatorcontrib><creatorcontrib>Fernandes, Larissa</creatorcontrib><creatorcontrib>Costa, Fabricio F.</creatorcontrib><creatorcontrib>Kioshima, Erika Seki</creatorcontrib><creatorcontrib>Abadio, Ana Karina Rodrigues</creatorcontrib><creatorcontrib>Bocca, Anamélia Lorenzetti</creatorcontrib><creatorcontrib>Felipe, Maria Sueli</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nicola, André Moraes</au><au>Albuquerque, Patrícia</au><au>Paes, Hugo Costa</au><au>Fernandes, Larissa</au><au>Costa, Fabricio F.</au><au>Kioshima, Erika Seki</au><au>Abadio, Ana Karina Rodrigues</au><au>Bocca, Anamélia Lorenzetti</au><au>Felipe, Maria Sueli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antifungal drugs: New insights in research &amp; development</atitle><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2019-03</date><risdate>2019</risdate><volume>195</volume><spage>21</spage><epage>38</epage><pages>21-38</pages><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>30347212</pmid><doi>10.1016/j.pharmthera.2018.10.008</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-7258
ispartof Pharmacology & therapeutics (Oxford), 2019-03, Vol.195, p.21-38
issn 0163-7258
1879-016X
language eng
recordid cdi_proquest_miscellaneous_2138636087
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Antibodies, Monoclonal - therapeutic use
Antifungal Agents - therapeutic use
Antifungal immunotherapy
Biological Products - therapeutic use
Drug Development
Drug discovery and development
Drug targets
Essential genes
Humans
Immunotherapy
Mycoses - therapy
Rational drug design
Systemic mycoses
Vaccines - therapeutic use
title Antifungal drugs: New insights in research & development
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A36%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antifungal%20drugs:%20New%20insights%20in%20research%20&%20development&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Nicola,%20Andr%C3%A9%20Moraes&rft.date=2019-03&rft.volume=195&rft.spage=21&rft.epage=38&rft.pages=21-38&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2018.10.008&rft_dat=%3Cproquest_cross%3E2138636087%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138636087&rft_id=info:pmid/30347212&rft_els_id=S016372581830192X&rfr_iscdi=true